Liprox

Lovastatin, the active ingredient in Liprox, is a HMG‑CoA reductase inhibitor presented as a oral tablet for oral use. It treats hypercholesterolemia and helps reduce cardiovascular risk in patients with elevated LDL cholesterol.

GNH USA supplies Liprox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lovastatin acts on cholesterol metabolism and is used for lipid‑lowering therapy.

Hypercholesterolemia: lowers LDL‑cholesterol levels and total cholesterol. Familial hypercholesterolemia: reduces elevated LDL in genetically predisposed patients. Cardiovascular disease prevention: decreases risk of myocardial infarction and stroke in individuals with high LDL cholesterol.

Lovastatin may cause a range of adverse reactions.

Common Side Effects: - Headache: mild to moderate intensity. - Gastrointestinal upset: including nausea, abdominal pain, or diarrhea. - Myalgia: muscle aches without weakness. - Elevated liver enzymes: mild transaminase increases. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Rhabdomyolysis: severe muscle breakdown with dark urine. - Severe liver injury: marked elevation of transaminases or hepatitis. - Allergic reactions: rash, pruritus, or angioedema. - Pancreatitis: abdominal pain with elevated pancreatic enzymes.

Before initiating therapy, certain precautions should be observed.

Liver function monitoring: assess baseline transaminases and repeat periodically. Muscle symptom monitoring: advise patients to report unexplained muscle pain or weakness. Avoid strong CYP3A4 inhibitors: concurrent use can increase lovastatin exposure. Pregnancy safety: use is generally contraindicated; assess risk‑benefit if exposure occurs. Store at room temperature: keep below 25 °C in the original pack, protect from moisture and light.

Lovastatin has notable drug‑interaction potential.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): may cause toxicity. - Gemfibrozil: increases risk of myopathy. - Danazol: elevates plasma concentrations.

Moderate Interactions (Monitor Closely): - Antacids (aluminum or magnesium): may reduce absorption. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring.